OTC Markets OTCPK - Delayed Quote USD

Coloplast A/S (CLPBF)

98.61

0.00

(0.00%)

At close: April 17 at 4:00:00 PM EDT

Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference call on 6 May 2025 at 11.00am CEST

Tuesday, 6 May 2025 at 11.00 - 12.00am CESTIn connection with the publication of Coloplast’s interim financial results for H1 2024/25, to be released same day around 07.30am CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the event. Colo

GlobeNewswire 5 days ago

CLPBF
0.00%
CLPBY
+1.33%
Coloplast AS (CLPBF) Q1 2025 Earnings Call Highlights: Strong Organic Growth and Strategic ...

Coloplast AS (CLPBF) reports robust 8% organic growth and a 27% EBIT margin, while addressing challenges in Interventional Urology and tax impacts.

GuruFocus.com 2 months ago

COLO-B.CO
Coloplast A/S - Allocation of Share Options

Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address: https://investor

GlobeNewswire 2 months ago

CLPBF
0.00%
CLPBY
+1.33%
Coloplast A/S - Interim Financial Report, Q1 2024/25

2024/25 Interim financial results, Q1 2024/25 1 October 2024 - 31 December 2024 Coloplast delivered 8% organic growth and an EBIT margin1 of 27% in Q1, in line with expectations. Reported revenue in DKK grew 6% and included negative impact from the divestment of Skin Care and currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 7%, Voice and Respiratory Care 11%, Advanced Wound Care 12% and Interventional Urology 1%.Growth in Chronic Care was driven by solid contrib

GlobeNewswire 2 months ago

CLPBF
0.00%
CLPBY
+1.33%
Stocks to watch this week: Amazon, Palantir, Disney, Novo Nordisk and AstraZeneca

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK 2 months ago

^FTSE

DIS

HMC
Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET (correction)

Tuesday, 4 February 2025 at 11.00 - 12.00am CET (corrected from 10.00 - 11.00am CET in an earlier version of this invitation)In connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The

GlobeNewswire 2 months ago

CLPBF
0.00%
CLPBY
+1.33%
Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET

Tuesday, 4 February 2025 at 10.00 - 11.00am CETIn connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the event. C

GlobeNewswire 2 months ago

CLPBF
0.00%
CLPBY
+1.33%
Coloplast A/S - Decisions at the Annual General Meeting 2024

Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2023/24 was approved.Distribution of year-end dividend of DKK 17.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2023/24 to DKK 22.00 per share

GlobeNewswire 4 months ago

CLPBF
0.00%
CLPBY
+1.33%
Coloplast divests core Skin Care product portfolio

The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area. Revenue from the core Skin Care business amounted to around DKK 400 million in FY 2023/24, with an operating profitability level significantly below the group EBIT margin. Coloplast’s FY 2024/25 financial guidance1 of organic revenue growth at 8-9% and an EBIT margin before special items of around 28% is unchanged and already includes the divestment

GlobeNewswire 4 months ago

CLPBF
0.00%
CLPBY
+1.33%
Kerecis included on the list of covered products for Diabetic Foot Ulcers in the final LCD policy

On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD)1 policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population. The final LCD policy confirms the introduction of a technical qualification and a clinical efficacy qualification, proposed in a draft LCD policy2 earlier this year. The final decision also i

GlobeNewswire 5 months ago

CLPBF
0.00%
CLPBY
+1.33%
Coloplast A/S - Notice of Annual General Meeting 2024

The Annual General Meeting of Coloplast A/S will be held onThursday, 5 December 2024 at 3:30 pm CETat the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark.The notice of the Annual General Meeting is enclosed. For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Aleksandra Dimovska Vice President, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email: dk

GlobeNewswire 5 months ago

CLPBF
0.00%
CLPBY
+1.33%
Coloplast AS (CLPBF) Q4 2024 Earnings Call Highlights: Strong Organic Growth and Strategic ...

Coloplast AS (CLPBF) reports robust financial performance with 8% organic growth and strategic product launches, despite facing supply disruptions and competitive pressures.

GuruFocus.com 5 months ago

COLO-B.CO
Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24

Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24 FY 2023/24 organic growth of 8% and 27% EBIT margin1. Reported revenue in DKK grew 10% to DKK 27,030 million. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 11%, Advanced Wound Care 10% (Advanced Wound Dressings 8%) and Interventional Urology 5%. Kerecis contributed 4%-points to reported growth, with an underlying growth of around 35%, in line with expectations. EBIT1 was DK

GlobeNewswire 5 months ago

CLPBF
0.00%
CLPBY
+1.33%
Coloplast A/S - Full-Year Financial Results 2023/24

2023/24 Announcement of full-year financial results 1 October 2023 - 30 September 2024 Coloplast delivered Q4 organic growth of 8% and an EBIT margin1 of 26%, which was negatively impacted by extraordinary costs and currencies. Reported revenue in DKK grew 12% with 3%-pts contribution from the Kerecis acquisition (two months). Organic growth rates by business area: Ostomy Care 6%, Continence Care 10%, Voice and Respiratory Care 12%, Advanced Wound Care 10% (Advanced Wound Dressings 4%) and Inter

GlobeNewswire 5 months ago

CLPBF
0.00%
CLPBY
+1.33%
Coloplast A/S - Announcement no. 05/2024 - Coloplast expands Executive Leadership Team

Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect. “We have entered the final year of our 2025 strategy. In this strategic period, Coloplast has made significant investments to expand the reach of the company and build four growth platforms, Chronic Care, Voice & Respiratory Care, Advanced Wound Care and Interventional Urology, which must drive value creation in the years to come. W

GlobeNewswire 5 months ago

CLPBF
0.00%
CLPBY
+1.33%
Stocks to watch this week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK 5 months ago

NGG

NGGTF

YUMC
Coloplast A/S - FY 2023/24 Earnings Release - Invitation for conference call on 5 November 2024 at 11.00 CET

Tuesday, 5 November 2024 at 11.00 – 12.00 CETIn connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial results and answer questions from investors and financial analysts.A presentation will be available on Coloplast's website approximately 1 hour before the conference call.Please note that the webcast of the conference call will be available during and after the event. Coloplast will be represented

GlobeNewswire 5 months ago

CLPBF
0.00%
CLPBY
+1.33%
Coloplast A/S - Financial Calendar 2024-25

Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://investor.coloplast.com/investor-relations/financial-calendar-and-events/ Kind regards,Investor RelationsColoplast A/STel. +45 4911 1800 For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458Email: dkadim@coloplast.com K

GlobeNewswire 6 months ago

CLPBF
0.00%
CLPBY
+1.33%
Recent Price Trend in Coloplast A/S Sponsored ADR (CLPBY) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Coloplast A/S Sponsored ADR (CLPBY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks 7 months ago

COLO-B.CO
Coloplast A/S - Interim Financial Report, 9M 2023/24

9M 2023/24Interim financial results, 9M 2023/241 October 2023 - 30 June 2024 Coloplast delivered 8% organic growth and an EBIT margin1) of 27% in Q3, with 11% growth in absolute EBIT1). Reported revenue in DKK grew 13% which includes 4%-points contribution from Kerecis (underlying growth of around 35%). Organic growth rates by business area: Ostomy Care 8%, Continence Care 8%, Voice and Respiratory Care 11%, Advanced Wound Care 13% (Advanced Wound Dressings 13%) and Interventional Urology 2%.Gro

GlobeNewswire 7 months ago

CLPBF
0.00%
CLPBY
+1.33%

Performance Overview

Return	CLPBF	OMX Copenhagen 25 Index (^OMXC25)
YTD	-9.62%	-11.30%
1-Year	-22.45%	-16.19%
3-Year	-32.09%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Coloplast A/S (CLPBF)

Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference call on 6 May 2025 at 11.00am CEST

Coloplast AS (CLPBF) Q1 2025 Earnings Call Highlights: Strong Organic Growth and Strategic ...

Coloplast A/S - Allocation of Share Options

Coloplast A/S - Interim Financial Report, Q1 2024/25

Stocks to watch this week: Amazon, Palantir, Disney, Novo Nordisk and AstraZeneca

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET (correction)

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET

Coloplast A/S - Decisions at the Annual General Meeting 2024

Coloplast divests core Skin Care product portfolio

Kerecis included on the list of covered products for Diabetic Foot Ulcers in the final LCD policy

Coloplast A/S - Notice of Annual General Meeting 2024

Coloplast AS (CLPBF) Q4 2024 Earnings Call Highlights: Strong Organic Growth and Strategic ...

Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24

Coloplast A/S - Full-Year Financial Results 2023/24

Coloplast A/S - Announcement no. 05/2024 - Coloplast expands Executive Leadership Team

Stocks to watch this week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S

Coloplast A/S - FY 2023/24 Earnings Release - Invitation for conference call on 5 November 2024 at 11.00 CET

Coloplast A/S - Financial Calendar 2024-25

Recent Price Trend in Coloplast A/S Sponsored ADR (CLPBY) is Your Friend, Here's Why

Coloplast A/S - Interim Financial Report, 9M 2023/24

Performance Overview